A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.

Kenneth G SaagPuja P KhannaRobert T KeenanSven OhlmanLisa Osterling KoskinenErik SparveAnn-Charlotte ÅkerbladMargareta WikénAlexander SoMichael H PillingerRobert Terkeltaub

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

Anakinra was not superior to triamcinolone for the primary end point, but had comparable efficacy in pain reduction and was favored for most secondary end points. Anakinra is an effective option for gout flares when conventional therapy is unsuitable.

Keyphrases

phase ii study
uric acid
open label
chronic pain
locally advanced
pain management
neuropathic pain
metabolic syndrome
clinical trial
spinal cord injury